PHARMATEK · Hématologie

Calculateur du score brut CISNE original de l’étude FINITE de 2015

Calculer la somme brute de 0 à 8 des composantes du CISNE original de l’étude FINITE et l’audit des valeurs saisies à partir d’une évaluation complète, vérifiée et initialement stable d’une neutropénie fébrile associée à une tumeur solide.

Révision clinique en cours

La révision clinique doit être complétée.

Cet outil fait partie de la bibliothèque PharmaTek. Son calcul reste indisponible au public jusqu’à la validation de sa formule, de ses limites et de ses sources.

Explorer les outils accessibles

Sources, population et validation

État: clinical-review-pending
Version de la méthode: Carmona-Bayonas et al. original validated 2015 FINITE CISNE raw arithmetic, engine cisne-finite-2015-original-raw-v1: add 2 for externally recorded ECOG performance status 2, 3, or 4; 2 for an independently clinician-established source-defined stress-induced-hyperglycemia category of present; 1 for chronic obstructive pulmonary disease present; 1 for chronic cardiovascular disease present; 1 for clinician-established source-compatible NCI mucositis grade 2 or higher; and 1 for an initial absolute monocyte count strictly <200 cells/µL, equivalently <0.2 ×10^9/L. Exact ECOG 2 and mucositis grade 2 contribute; exact monocytes 200 cells/µL or 0.2 ×10^9/L contribute zero. A verified absolute monocyte count in ×10^9/L is multiplied by exactly 1000 before the strict cells/µL comparison; no rounding or imputation is used. The published 2011 precursor and current author calculator print glucose >=121 mg/dL but a dimensionally inconsistent >=250 mg/m² branch for diabetes, with the current calculator also mentioning steroid treatment; secondary sources silently replace that unit. This source-locked engine accepts no glucose, diabetes, steroid, or HbA1c input, never repairs or applies the disputed threshold, and requires an independently clinician-established source category plus acknowledgement that the discrepancy was reviewed. Fourteen exact confirmations require adult solid-tumor mild- or moderate-intensity-chemotherapy source applicability; independently established chemotherapy-associated febrile neutropenia; no hospitalization for another reason at episode onset; one complete same-episode assessment within the initial three hours; no acute organ failure or decompensated chronic insufficiency; no septic shock, hypotension, or abnormal-vital-sign instability; no severe infection; no other serious complication independently requiring admission; independently clinician-established ECOG, COPD, cardiovascular, and mucositis categories; verified initial-CBC absolute-monocyte identity, unit, and timing; independently established stress-hyperglycemia category with the published-unit discrepancy reviewed; complete-case use without imputation; urgent assessment and initial empiric antibacterial care not delayed; and serial reassessment, current-era transport, and raw-documentation-only limitations acknowledged. Output is limited to version, the raw integer 0–8 sum, six component contributions, and exact entered/normalized audit; no low/intermediate/high class, cutoff, probability, outcome estimate, prognosis, diagnosis, eligibility, admission or discharge decision, outpatient selection, antimicrobial or other treatment advice, monitoring, disposition, management, or recommendation is supplied.
Population: Qualified clinicians documenting the frozen original 2015 FINITE raw arithmetic for an adult with a solid tumor, independently established chemotherapy-associated febrile neutropenia after mild- or moderate-intensity chemotherapy, and independently established initial apparent stability. The 2011 precursor reviewed 861 valid outpatient episodes from 1996–2004 and identified 692 apparently stable episodes. The formal FINITE validation prospectively recruited 1,133 adults with seemingly stable episodes at 25 hospitals during 2012–2014. This v1 requires no hospitalization for another reason at episode onset; one complete same-episode assessment within the first three hours; exclusion of acute organ failure or decompensated chronic insufficiency, septic shock, hypotension or other abnormal-vital-sign instability, severe infection, and every other serious complication independently requiring admission; externally recorded ECOG 0–4; independently established COPD, chronic-cardiovascular-disease, source-compatible NCI-mucositis, and source-defined stress-hyperglycemia categories; and a verified initial-CBC absolute monocyte count. CISNE is applied only after stability is established, never to establish stability, and current use requires urgent care, serial reassessment, and explicit historical-to-current-era transport acknowledgement.
Limites et exclusions: Pediatric use; hematologic malignancy or lymphoma; acute leukemia; hematopoietic stem-cell or bone-marrow transplantation; high-dose or intensification chemotherapy; Magrath or another Burkitt induction regimen; inpatient-onset febrile neutropenia or hospitalization for another reason; or use to establish a solid-tumor diagnosis, febrile neutropenia, chemotherapy attribution, initial stability, source applicability, or eligibility for a care pathway. · Acute renal, cardiac, or respiratory organ failure; decompensated chronic insufficiency; septic shock; hypotension; abnormal vital-sign instability; severe infection; another serious complication or independent admission criterion; an assessment outside or mixed across the initial same-episode three-hour window; or any missing, unknown, inferred, imputed, defaulted, carried-forward, later, post-treatment, or mixed-time input. · An app-inferred or converted ECOG grade; unsupported COPD, chronic-cardiovascular-disease, or mucositis definitions; mucositis not independently classified under a source-compatible NCI grade; total leukocytes, neutrophils, a monocyte percentage, or another identity substituted for the initial absolute monocyte count; unsupported units or timing; monocytes <=200 rather than <200; or a glucose, diabetes, steroid, HbA1c, corrected unit, or secondary-source threshold used to derive stress hyperglycemia instead of the independently established source category. · The 2011 precursor variable labels chronic bronchitis, chronic heart failure, or stomatitis substituted for the formal 2015 COPD, chronic cardiovascular disease, and NCI mucositis components; MASCC; the distinct 2016 continuous CISNE nomogram or its points/probability; a third-party variant; or any changed component, weight, operator, unit conversion, assessment window, population, or incomplete-case arithmetic. · Any 0, 1–2, or >=3 class; low, intermediate, or high label; cutoff; serious-complication or mortality probability; outcome estimate; individual prognosis; diagnosis; admission, discharge, outpatient eligibility, or other disposition; antimicrobial timing or selection; treatment; monitoring; management; recommendation; or delay to urgent assessment, empiric antibacterial care, or serial reassessment. · Reproduction or adaptation of ASCO article prose, tables, figures, the author calculator's code or interface, or third-party logos, branding, or visual identity; or an implication of author, ASCO, ECOG-ACRIN, or other organizational endorsement. The arithmetic is independently implemented from publication-reported facts; the 2015 article is ASCO-copyrighted, the author calculator exposes no implementation license, and nominative CISNE use remains subject to clinical and legal review.

Origine de l’outil PharmaTek

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source: PharmaTek · MDose
Version importée: 4b66536936ed
État de publication: Révision clinique en cours

POURSUIVRE AVEC MDOSE

Un outil. Un premier lien.

Recevez des nouvelles des outils ou discutez d’une collaboration. L’utilisation de PharmaTek reste accessible sans laisser vos coordonnées.

Médecins et partenaires